DC preparations for therapy
- 1 April 2004
- journal article
- review article
- Published by Elsevier BV in Cytotherapy
- Vol. 6 (2), 99-104
- https://doi.org/10.1080/14653240410005285
Abstract
This review describes and compares the different DC preparations currently under laboratory and clinical investigation as vehicles for cancer immunotherapy.Keywords
This publication has 44 references indexed in Scilit:
- Competent dendritic cells derived from CD34+ progenitors express CMRF‐44 antigen early in the differentiation pathwayImmunology & Cell Biology, 2002
- IFN‐α enhances CD40 ligand‐mediated activation of immature monocyte‐derived dendritic cellsInternational Immunology, 2002
- The disabled dendritic cellThe FASEB Journal, 2001
- Broadsheet: Dendritic cells and their emerging clinical applicationsPathology, 2001
- Dendritic cells: from ontogenetic orphans to myelomonocytic descendantsImmunology Today, 1996
- Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.The Journal of Experimental Medicine, 1995
- CD34+ Human Hemopoietic Progenitor Cells of the Bone Marrow Differ from Those of the Peripheral Blood: An Immunocytochemical and Morphometric StudyActa Haematologica, 1995
- Proliferating dendritic cell progenitors in human blood.The Journal of Experimental Medicine, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cellsNature, 1992